


Global Prurigo Nodularis Treatment Market is Projected to Reach USD 930.9 Million by 2033 Growing at a 3.0% CAGR | FMI

The lack of awareness about rare diseases like prurigo nodularis and available treatment options is anticipated to impede market growth.

NEWARK, DE, UNITED STATES, February 5, 2025 /EINPresswire.com/ -- The [global prurigo nodularis treatment market](https://www.futuremarketinsights.com/report-sample#5245502d47422d33333339) is set for significant expansion, with estimates placing its value at USD 693.3 million in 2023, according to a recent report from Future Market Insights. The market is projected to grow at a CAGR of 3.0% over the next decade, potentially reaching USD 930.9 million by 2033.

Prurigo nodularis, a rare and debilitating dermatological condition, is characterized by intensely itchy, inflamed nodules that severely impact patients' quality of life. Due to rising awareness and increased research into rare diseases, the regulatory environment is becoming more favorable, with accelerated approval pathways expediting the introduction of new treatments.



□□□□□□□ □□□ □□□□□□ □□ □□□ □□□□□□: □□□□□□□ □□□□ □□□□□□ □□□□□□□!

<https://www.futuremarketinsights.com/report-sample#5245502d47422d33333339>


This shift, along with ongoing advancements in orphan drug development, is expected to drive greater investment in innovative therapies, further fueling market growth. As demand for effective treatment solutions continues to rise, pharmaceutical companies are focusing on new drug formulations and targeted therapies to address this unmet medical need.

Global market overview:
 The increasing number of reported cases worldwide has led to greater demand for effective treatments.

Emerging biologics, targeted therapies, and novel corticosteroids are expanding treatment options.

Improved awareness among healthcare providers and patients is leading to earlier diagnosis and intervention.

Key pharmaceutical companies are investing in research and development, with promising therapies receiving regulatory approvals.



Regional Analysis of Prurigo Nodularis Treatment Market

Key pharmaceutical companies are investing in research and development, with promising therapies receiving regulatory approvals.

“

United Kingdom is said to hold a profitable market during the forecast period, driven by the increasing prevalence of prurigo nodularis disorder in the region expanding at a CAGR of 2.1%.”

Future Market Insights

the forecast period.

North America held a 14.9% revenue share in the prurigo nodularis treatment market in 2022, with further expansion anticipated.

Global market overview:

The global prurigo nodularis treatment market grew at a steady pace of 2.8% CAGR from 2017 to 2022.


Europe continues to be the leading market, accounting for 58.6% of global revenue share in 2022.

Germany, a key European market, is expected to maintain its dominance, growing at a robust CAGR of 5.1% during

- The Japanese market is considered one of the most developed globally, with a market share of 4.0%.

- China's growing economy has resulted in a significant market boom, with a projected CAGR of 3.6%.

- Capsaicin cream remains a market leader, accounting for 40.34% of the prurigo nodularis treatment market share in 2022.



- Retail pharmacies have been a major distribution channel, representing 53.10% of revenue share in 2022.

As treatment options for prurigo nodularis continue to improve, the market is poised for continued growth driven by innovative therapies, regulatory support, and expanding awareness. With key players focusing on research and development, the next decade looks promising for the treatment of this rare condition.

“Innovations in new treatment options and increasing demand for capsaicin cream are the prominent drivers to raise the market growth of the Prurigo Nodularis Treatment”, says comments a Future Market Insights Analyst.

Future Market Insights (FMI) is a leading market research and consulting firm. For more information, visit: <https://www.futuremarketinsights.com/reports/prurigo-nodularis-treatment-and-management-market>

Future Market Insights (FMI) is a leading market research and consulting firm. For more information, visit: <https://www.futuremarketinsights.com/reports/prurigo-nodularis-treatment-and-management-market>

- Bayer AG
- Pfizer Inc.
- GlaxoSmithKline Plc.
- Teva Pharmaceutical Industries Ltd.
- Johnson & Johnson
- Merck & Co. Inc.
- Sanofi SA
- Takeda Pharmaceutical Company Limited
- Novartis AG
- Celgene Corporation
- Galderma SA (Nestle Skin Health Company)

- VYNE Therapeutics Inc.

□□□□ □□ □□□ □□□□□□□□□□ □□□□□□□□□□□□ □□ □□□ □□□ □□□□□□□ □□ □□□ □□□□□□ □□□:

• In June 2023, The Janssen Pharmaceutical Companies of Johnson & Johnson announced results from an interim analysis of Cohort 1 of the Phase 3 THOR study, evaluating treatment with BALVERSA® (erdafitinib) versus chemotherapy in patients with metastatic or unresectable urothelial carcinoma (UC) and selected fibroblast growth factor receptor (FGFR) gene alterations who had received prior treatment with an anti-programmed death ligand 1 (PD-[L]1) agent.

• The study met its primary endpoint of overall survival (OS) and reduced the risk of death by 36 percent. 1 Following the accelerated approval of BALVERSA® in 2019, these confirmatory data were featured in a Late-Breaking Presentation Session (Abstract # LBA4619) at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting.

□□□□□□□□□ □□□□ □□□□□□□□□□ □□□□□□□□ □□□□ □□□□-□□□□ □□□□!

<https://www.futuremarketinsights.com/industry-analysis/therapy-area>

□□□ □□□□□□□□□□□□:

□□ □□□□ □□□□□:

- Corticosteroids
 - o Topical
 - o Oral
 - o Emollients
 - o Capsaicin Cream
 - o Antihistamines
 - o Anticonvulsants
 - o Antidepressants
 - o Neurokinin 1 Receptor (NK1R)
 - o Opiate Receptor Antagonists
 - o Others

□□ □□□□□□□□□□□□ □□□□□□□:

- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies

□□ □□□□□□:

- North America
- Latin America
- Europe
- South Asia

- East Asia
- Oceania
- The Middle East & Africa

□□□□□□ □□□'□ □□□□□□□ □□□□□□ □□□□□□□□ □□ □□□□□□□□□□ □□□□□□ □□□□□□□□ □□□□□□:

□□□□ □□□□□□□□□□□ □□□□□□ □□□□: <https://www.futuremarketinsights.com/reports/skin-replacement-market>

□□□□□□ □□□□□□□□□□ □□□□□□□□ □□□□□□ □□□□□□: <https://www.futuremarketinsights.com/reports/atopic-dermatitis-treatment-market>

□□□□□□ □□□□□□□□□□ □□□□□□ □□□□□□: <https://www.futuremarketinsights.com/reports/allergy-diagnostics-market>

□□□□□□□□ □□□□□□ □□□□□□ □□□□□□: <https://www.futuremarketinsights.com/reports/skin-care-devices-market>

□□□□ □□□□□ □□□□□□ □□□□□□□□□□□□□□ □□□□□□□□□□□ □□□□□□ □□□□□□: <https://www.futuremarketinsights.com/reports/oral-solid-dosage-pharmaceutical-formulation-market>

□□□-□□□□□□□□□□ □□ □□□□□□□□ □□□□ □□□□□□□□ □□□□□□□□□□ □□□□□□□□□□: <https://www.futuremarketinsights.com/reports/mri-compatible-iv-infusion-pump-systems-market>

□□□□ □□□□□□□□□□ □□□□□□ □□□□ □□□□□□□□ □□□□□□□□□□ □□□□□□□□ □□□□□□□□□□: <https://www.futuremarketinsights.com/reports/oral-controlled-release-drug-delivery-technology-market>

□□□□ □□□□□□ □□□□ □□□□□□ □□□□□□□□□□□: <https://www.futuremarketinsights.com/reports/farm-animal-drugs-market>

□□□□□□□□ □□□□□□□ □□□□□ □□□□□□ □□□□□□□□□□: <https://www.futuremarketinsights.com/reports/diabetic-macular-edema-market>

□□□□□ □□ □□□□□□ □□□□□□□ □□□ □□□□□□□□□□ □□□□□□: <https://www.futuremarketinsights.com/reports/dermal-fillers-and-botulinum-toxin-market>

□□□□□ □□□□□□ □□□□□□ □□□□□□□□□□ (□□□□)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors

that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

□□□□□□ □□:

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware - 19713, USA
T: +1-347-918-3531
For Sales Enquiries: sales@futuremarketinsights.com
Website: <https://www.futuremarketinsights.com>
[LinkedIn](#) | [Twitter](#) | [Blogs](#) | [YouTube](#)

Ankush Nikam
Future Market Insights, Inc.
+91 90966 84197
[email us here](#)

Visit us on social media:

[Facebook](#)
[X](#)
[LinkedIn](#)
[YouTube](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/783053144>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2025 Newsmatics Inc. All Right Reserved.